Inactive Instrument

Small Pharma Inc.

Equities

DMT

CA8316641072

Biotechnology & Medical Research

Small Pharma : Consultant Psychiatrist Dr. David Erritzoe discusses our Phase IIa Study

January 31, 2023 at 09:58 am

31 January 2023

Insights

Consultant Psychiatrist Dr. David Erritzoe discusses our Phase IIa Study

Dr. David Erritzoe, Consultant Psychiatrist & Chief Investigator of Small Pharma's SPL026 Phase I/IIa Study, shares his thoughts on our latest results exploring a short-duration psychedelic for depression, and why this is exciting for the field of psychiatry.

David, PhD, is a Clinical Director and Deputy Head in Centre for Psychedelic Research under the Division of Psychiatry at Imperial College London.

Company Updates

Attachments

Original Link
Original Document
Permalink

Disclaimer

Small Pharma Inc. published this content on 31 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 January 2023 14:57:01 UTC.

Latest news about Small Pharma Inc.

Small Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	01-29	CI
Small Pharma Brief: Cybin Completed Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics	23-10-23	MT
Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).	23-10-22	CI
Small Pharma Brief: Shareholders overwhelmingly voted in favour of Cybin's acquisition	23-10-19	MT
Small Pharma Brief: Q2 FY24 Highlights Include Cash on hand as of August 31, 2023 of approximately C$7.7 million	23-10-19	MT
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	23-10-19	CI
Small Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	23-10-19	CI
Small Pharma Notes Positive Top-line Data from SPL026-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	23-09-26	MT
Small Pharma Brief: Reporting "Positive" Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	23-09-26	MT
Small Pharma Inc. Reports Positive Top-line Data from SPL026 (DMT-SSRI Drug Interaction Study in Patients with Major Depressive Disorder	23-09-26	CI
Cybin Agrees to Acquire Small Pharma in All-Share Deal	23-08-28	MT
Transcript : Small Pharma Inc., Cybin Inc. - M&A Call	23-08-28
Small Pharma Inc.'s Equity Buyback announced on August 18, 2022, has expired with 1,788,000 shares, representing 0.55% for CAD 0.48 million.	23-08-17	CI
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	23-07-26	CI
Small Pharma Inc. Reports Earnings Results for the First Quarter Ended May 31, 2023	23-07-26	CI
Small Pharma Announces SPL028 R&D Strategy Update; Separately Announced Management Team Change	23-07-05	MT
Small Pharma Inc. Announces Management Changes	23-07-05	CI
Small Pharma Announces SPL028 R&D Strategy Update	23-07-05	CI
Small Pharma Inc. Announces Executive Team Change	23-07-05	CI
Small Pharma Brief: Notes "Operational Efficiencies Underway To Deliver Meaningful Runway Extension"	23-06-28	MT
Small Pharma Brief: For FY23, Adds Preliminary findings from SPL028 Phase I clinical trial support target drug profile	23-06-28	MT
Small Pharma Brief: For FY23, Says Multiple clinical milestones achieved including Frst proof-of-concept for DMT-based therapies from a blinded placebo-controlled study	23-06-28	MT
Small Pharma Brief: Says Cash on hand as of February 28, 2023 was approximately $18.5 million	23-06-28	MT
Tranche Update on Small Pharma Inc.'s Equity Buyback Plan announced on August 18, 2022.	23-06-28	CI
Small Pharma Inc. Reports Earnings Results for the Full Year Ended February 28, 2023	23-06-28	CI

Chart Small Pharma Inc.

Duration

Period

More charts

Company Profile

Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of depression. It has a portfolio of clinical-stage dimethyltryptamine (DMT)-based assets, SPL026 and SPL028. It has a pipeline of proprietary preclinical assets. Its clinical-stage program, SPL026, a first-generation DMT molecule, has shown proof-of-concept for the potential treatment of MDD. In a Phase IIa study, IV SPL026 demonstrated a rapid and durable antidepressant effect, as well as a favorable safety and tolerability profile. Small Pharma is also advancing SPL028, a second-generation injectable deuterated DMT molecule, in a Phase I trial.

Sector

Biotechnology & Medical Research

Calendar

2024-07-25 - Q1 2025 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+46.17%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research